SREBF1 and metabolic dysfunction-associated steatotic liver disease: These findings establish VD3 as a potential adjunctive treatment to counteract tamoxifen-associated NAFLD, offering a novel therapeutic strategy based on SREBP1 activity to prevent lipid metabolism disorders in breast cancer patients undergoing tamoxifen therapy [76].